Viking Therapeutics (NasdaqCM:VKTX) experienced a share price increase of 10% last week, coinciding with the announcement of a multi-year manufacturing agreement with CordenPharma for its V2735 ...
Less than a year after CordenPharma earmarked a major chunk of change to beef up in peptide manufacturing for GLP-1s and ...
Zacks.com on MSN7d
VKTX Inks Manufacturing Deal With CordenPharma for Obesity Drug SupplyThe deal provides Viking Therapeutics with a secured dedicated annual supply of both injectable and oral versions of its ...
Zacks Investment Research on MSN6d
How to Play VKTX Stock Amid Manufacturing Deal With CordenPharmaShares of Viking Therapeutics VKTX gained more than 11% on Wednesday after the company announced that it had signed a broad ...
Viking announced a supply deal with CordenPharma that sets it up for a standalone path to the obesity market. Read why I ...
Over the past few days, as the rest of the stock market melted down, a revolution has been quietly brewing in the market for ...
Viking Therapeutics eyes billion-dollar obesity drug markets with pivotal trials and major production deals. Read more about ...
The biotech will commit $150 million to an alliance that hands it significant production capacity for a closely watched ...
Viking Therapeutics has contracted CDMO CordenPharma for a total of $150 million to make billions of clinical and commercial ...
Investor's Business Daily on MSN8d
Viking Therapeutics Just Inked A $150 Million Manufacturing Deal. Here's Why Shares Crumbled.Viking Therapeutics stock toppled Tuesday after the biotech company inked a $150 million manufacturing deal for its weight-loss drug, VK2735.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback